David C Currow1, Hui You2, Sanchia Aranda3, Brian C McCaughan4, Stephen Morrell2, Deborah F Baker2, Richard Walton2, David M Roder5. 1. Cancer Institute NSW, Sydney, NSW, Australia. david.roder@unisa.edu.au. 2. Information Analysis Unit, Cancer Institute NSW, Sydney, NSW, Australia. 3. Cancer Institute NSW, Sydney, NSW, Australia. 4. Royal Prince Alfred Hospital, Sydney, NSW, Australia. 5. School of Population Health, University of South Australia, Adelaide, SA, Australia.
Abstract
OBJECTIVE: To investigate opportunities to reduce lung cancer mortality after diagnosis of localised non-small cell lung cancer (NSCLC) in New South Wales through surgical resection. DESIGN, PATIENTS AND SETTING: In this cohort study, resection rates and lung cancer mortality risk were explored using multivariate logistic regression and competing risk regression, respectively. Data for 3040 patients were extracted from the NSW Central Cancer Registry for the diagnostic period 1 January 2003 to 31 December 2007. Subset analyses for patients at low surgical risk indicated resection rates and outcomes under ideal circumstances. MAIN OUTCOME MEASURES: Resection rates and lung cancer mortality. RESULTS: The resection rate in NSW was estimated to be between 38% and 43%, peaking at 59% by local health district (LHD) of residence. Not having a resection was associated with older age, lower socioeconomic status, lack of private health insurance, and residence by LHD. Adjusted 5-year cumulated probabilities of death were 76% in absence of resection, 30% for wedge resection, 18% for segmental resection, 22% for lobectomy and 45% for pneumonectomy. Of 255 "low surgical risk" patients, 71% had a resection. Those not receiving a resection had a higher probability of death (adjusted subhazard ratio, 14.1; 95% CI, 7.2-27.5). If the low overall resection rate of 38%-43% in NSW were increased to 59% (the highest LHD resection rate), the proportion of all patients with localised NSCLC dying of NSCLC in the 5 years from diagnosis would decrease by about 10%, based on differences in probabilities of death by resection estimated in this study. CONCLUSIONS: Potential exists to reduce deaths from NSCLC in NSW through increased resection.
OBJECTIVE: To investigate opportunities to reduce lung cancer mortality after diagnosis of localised non-small cell lung cancer (NSCLC) in New South Wales through surgical resection. DESIGN, PATIENTS AND SETTING: In this cohort study, resection rates and lung cancer mortality risk were explored using multivariate logistic regression and competing risk regression, respectively. Data for 3040 patients were extracted from the NSW Central Cancer Registry for the diagnostic period 1 January 2003 to 31 December 2007. Subset analyses for patients at low surgical risk indicated resection rates and outcomes under ideal circumstances. MAIN OUTCOME MEASURES: Resection rates and lung cancer mortality. RESULTS: The resection rate in NSW was estimated to be between 38% and 43%, peaking at 59% by local health district (LHD) of residence. Not having a resection was associated with older age, lower socioeconomic status, lack of private health insurance, and residence by LHD. Adjusted 5-year cumulated probabilities of death were 76% in absence of resection, 30% for wedge resection, 18% for segmental resection, 22% for lobectomy and 45% for pneumonectomy. Of 255 "low surgical risk" patients, 71% had a resection. Those not receiving a resection had a higher probability of death (adjusted subhazard ratio, 14.1; 95% CI, 7.2-27.5). If the low overall resection rate of 38%-43% in NSW were increased to 59% (the highest LHD resection rate), the proportion of all patients with localised NSCLC dying of NSCLC in the 5 years from diagnosis would decrease by about 10%, based on differences in probabilities of death by resection estimated in this study. CONCLUSIONS: Potential exists to reduce deaths from NSCLC in NSW through increased resection.
Authors: Éilis Dockry; Seónadh O'Leary; Laura E Gleeson; Judith Lyons; Joseph Keane; Steven G Gray; Derek G Doherty Journal: Oncoimmunology Date: 2018-02-12 Impact factor: 8.110
Authors: Stuart Purdie; Nicola Creighton; Kahren Maree White; Deborah Baker; Dan Ewald; Chee Khoon Lee; Alison Lyon; Johnathan Man; David Michail; Alexis Andrew Miller; Lawrence Tan; David Currow; Jane M Young Journal: NPJ Prim Care Respir Med Date: 2019-02-08 Impact factor: 2.871
Authors: Alison Gibberd; Rajah Supramaniam; Anthony Dillon; Bruce K Armstrong; Dianne L O'Connell Journal: BMC Cancer Date: 2016-04-25 Impact factor: 4.430